Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898646 · ClinicalTrials.gov registry record · Phase 2

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

A Phase 2 study of AL Amyloidosis, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
96
Enrollment target
2
Study locations

NCT05898646 is a Phase 2 study of AL Amyloidosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 96 participants, below the 418-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898646, a Phase 2 study of AL Amyloidosis, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following initial therapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Daratumumab is commonly prescribed as initial treatment for patients with AL amyloidosis. However, it is not known what role daratumumab may play in the maintenance therapy period of patients with AL amyloidosis. This phase II trial compares shorter duration maintenance to longer duration maintenance for improving survival in patients with AL amyloidosis.

Conditions Studied

AL Amyloidosis

Interventions

  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Echocardiography Test
  • OTHER Questionnaire Administration
  • PROCEDURE X-Ray Imaging
  • BIOLOGICAL Daratumumab

Study Locations (2)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2023-07-17
Est. Completion 2026-12
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05898646

The ClinicalTrials.gov registry entry for NCT05898646 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (77% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 5 interventions - of which Bone Marrow Aspiration is the first listed.

NCT05898646 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05898646 about?

NCT05898646 is a clinical study titled "Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial". This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab for light chain (AL) amyloidosis. Maintenance therapy is treatment that is given to help keep cancer from ...

What is the current status of trial NCT05898646?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2023-07-17. Estimated completion is 2026-12.

What conditions does trial NCT05898646 study?

This clinical trial studies the following conditions: AL Amyloidosis.

What interventions are being tested in trial NCT05898646?

The interventions under investigation include: Bone Marrow Aspiration (PROCEDURE), Echocardiography Test (PROCEDURE), Questionnaire Administration (OTHER), X-Ray Imaging (PROCEDURE), Daratumumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05898646?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898646 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for AL Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

AL Amyloidosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.